Clinical trials: Neurological Disease Without Cognitive Degradation
Probable Alzheimer Disease, Parkinson Disease
In Vivo Alzheimer Proteomics
In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which represents, as in other developed countries, a major public health issue.
- Conditions
- Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation, Brain Trauma
- Trial name
- PROMARA (NCT02263235)
- Testing
- administration of stable isotope-labelled leucine-, collection of CSF, blood, urine, saliva
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Montpellier